Hye-Jung E. Chun

Hye-Jung E. Chun

Auto-generated profile, based on publicly available information

Hye-Jung E. Chun

Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2025 in bioRxiv
Verified
Preprint
Open access
LLLovelace J. Luquette
Lovelace J. Luquette
TCTim H. H. Coorens
Tim H. H. Coorens
ANAbhiram Natu
Abhiram Natu
MSMilovan Suvakov
Milovan Suvakov
ACAnn Caplin
Ann Caplin
AAAlexij Abyzov
Alexij Abyzov
Single-cell DNA sequencing offers a powerful means of studying somatic mosaicism but requires careful analysis to mitigate DNA amplification-related artifacts. We performed primary template-directed amplification (PTA) and sequencing of 102 nuclei from postmortem lung and colon tissues of a 74-year-old male. Single-cell mutation burdens and spectra were validated by duplex sequencing and revealed heterogeneity across organs and cells, including signatures of APOBEC activity and tobacco exposure. Cells from both tissues exhibited chromosomal aneuploidies, loss of chromosome Y, and chromosomal rearrangements including rearrangements of the T-cell receptor loci indicative of T-cells. Shared embryonic mutations between cells enabled reconstruction of cellular ancestries from the zygote, which were validated by bulk sequencing. Collectively, we demonstrate a comprehensive approach for single-cell genomics that yields an expansive view of diverse somatic mutation types from development through aging across diverse tissues—insights that are obscured in bulk sequencing and only partially captured by other single-cell methods.

9 August 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
VFVictoria Elisabeth Fincke
Victoria Elisabeth Fincke
MSMona Steinbügl
Mona Steinbügl
HCHye-Jung E. Chun
Hye-Jung E. Chun
KNKarolina Nemes
Karolina Nemes
MMMarlena Mucha
Marlena Mucha
MFMichael C. Frühwald
Michael C. Frühwald
Purpose: Extracranial malignant rhabdoid tumors (eMRT) are a challenging entity. Despite the use of multimodal treatment approaches, therapy failure occurs in 55% to 67% of these. Molecular markers for identification of patients at increased risk for relapse or refractory (R/R) disease are not available. Clinical characteristics may only insufficiently predict the individual course of disease. Experimental Design: Using the EU-RHAB database, we analyzed a cohort of 121 patients with eMRT clinically. For 81 patients, molecular and clinical data were available, which were further complemented with publicly available DNA molecular data from 92 eMRTs. We aimed to delineate molecular risk factors by dissecting the DNA methylome of these tumors. Moreover, we establish clinical characteristics and treatment details of R/R disease in a subcohort of 80 patients. Results: Using consensus hierarchical clustering, we identified three distinct subgroups, one of which (eMRT standard risk) was associated with significantly improved survival, irrespective of germline status and/or localization. At the transcriptome level, this subgroup was characterized by an overexpression of genes involved in muscle development. A relevant proportion of patients developed distant relapses or progressions; the median time to the event was 4 months, underlining the need for early identification and risk stratification of R/R disease. The overall survival was significantly decreased in patients with progressive disease when compared with relapse cases, and reaching complete remission during salvage therapy provided a survival benefit. Conclusions: Our analysis of eMRT in this comprehensive cohort provides novel insights into the patterns of relapse and integrates molecular and clinical risk factors to guide clinical decision-making.

7 October 2025 in bioRxiv
Verified
Preprint
Open access
SWSeunghyun Wang
Seunghyun Wang
MBMingyun Bae
Mingyun Bae
JWJinhao Wang
Jinhao Wang
BZBoxun Zhao
Boxun Zhao
KNKhue Nguyen
Khue Nguyen
ELEunjung Alice Lee
Eunjung Alice Lee
Mobile element insertions (MEI) shape the human genome in both germline and somatic tissues. While inherited MEIs are well characterized, mapping somatic MEIs (sMEI) in non-cancer tissues remains challenging due to their low allelic fraction and repetitive nature. We established an integrative framework for sMEI analysis leveraging modern sequencing technologies and analytical innovations. We first benchmarked sMEI detection and demonstrated advantages of long-read and MEI-targeted sequencing for ultra-low-frequency events using a mixture of well-established cell lines. We then showed that haplotype phasing and donor-specific assemblies refine sMEI detection, effectively distinguishing from germline and false signals in in-silico tumor-normal mixtures. We further developed a source-tracing strategy based on internal sequence variation, expanding the catalogue of active source elements beyond traditional transduction-based methods. Applying this framework to donor tissues, we identified 18 rare somatic L1 insertions, revealing structural and source diversity. Our work provides a foundational framework and biological insight into sMEIs.

14 October 2025 in bioRxiv
Verified
Preprint
Open access
YHYoo-Jin Jiny Ha
Yoo-Jin Jiny Ha
DMDominika Maziec
Dominika Maziec
JMJulia Markowski
Julia Markowski
SGStephanie J. Georges
Stephanie J. Georges
NPNancy L. Parmalee
Nancy L. Parmalee
PPPeter Park
Peter Park
Mosaic mutations in normal tissues occur at low variant allele fractions (VAFs), complicating detection. To benchmark strategies, the SMaHT Network created a cell-line mixture (1:49) and produced ultra-deep whole-genome sequencing using short and long reads (five centers, 180–500× each). We assembled a reference of 44,008 mosaic SNVs and 2,059 Indels, cross-validation between platforms to expose limits of short-read analysis. We also partitioned the genome by mappability to examine the impact of genomic context, added a negative reference set, and accounted for culture-derived mutations. When seven institutions applied eleven algorithms to mixture data, call sets were largely discordant across tools and replicates, partly reflecting stochastic presence of low-VAF mutations in biological replicants. For >2% VAF SNVs, sensitivity and precision approached ∼80% at ≥300×, with little gain from additional sequencing. This work provides a comprehensive framework for reliable detection of low-VAF mutations in non-cancer tissues and a valuable resource for the community.

15 October 2024
Verified
Other
Open access
VFVictoria Elisabeth Fincke
Victoria Elisabeth Fincke
MSMona Steinbügl
Mona Steinbügl
HCHye-Jung E. Chun
Hye-Jung E. Chun
KNKarolina Nemes
Karolina Nemes
MMMarlena Mucha
Marlena Mucha
MFMichael C. Frühwald
Michael C. Frühwald
Results of differential gene expression analysis

15 October 2024
Verified
Other
Open access
VFVictoria Elisabeth Fincke
Victoria Elisabeth Fincke
MSMona Steinbügl
Mona Steinbügl
HCHye-Jung E. Chun
Hye-Jung E. Chun
KNKarolina Nemes
Karolina Nemes
MMMarlena Mucha
Marlena Mucha
MFMichael C. Frühwald
Michael C. Frühwald
Copy number alterations for extracranial malignant rhabdoid tumors